Beijing Leadman Biochemistry Co Ltd (SHE:300289) — Market Cap & Net Worth
Market Cap & Net Worth: Beijing Leadman Biochemistry Co Ltd (300289)
Beijing Leadman Biochemistry Co Ltd (SHE:300289) has a market capitalization of $467.29 Million (CN¥3.19 Billion) as of June 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #12761 globally and #3779 in its home market, demonstrating a 6.34% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Beijing Leadman Biochemistry Co Ltd's stock price CN¥5.87 by its total outstanding shares 544011487 (544.01 Million). Review 300289 liabilities breakdown to assess the company's total debt and financial obligations.
Beijing Leadman Biochemistry Co Ltd Market Cap History: 2015 to 2026
Beijing Leadman Biochemistry Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.56 Billion to $467.29 Million (-9.61% CAGR).
Beijing Leadman Biochemistry Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Beijing Leadman Biochemistry Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.70x
Beijing Leadman Biochemistry Co Ltd's market cap is 1.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $978.46 Million | $533.39 Million | $69.65 Million | 1.83x | 14.05x |
| 2017 | $723.48 Million | $575.98 Million | $73.07 Million | 1.26x | 9.90x |
| 2018 | $520.77 Million | $654.80 Million | $40.47 Million | 0.80x | 12.87x |
| 2019 | $459.92 Million | $515.14 Million | $6.31 Million | 0.89x | 72.90x |
| 2020 | $466.33 Million | $471.51 Million | -$50.98 Million | 0.99x | N/A |
| 2021 | $638.93 Million | $564.06 Million | $22.42 Million | 1.13x | 28.50x |
| 2022 | $457.55 Million | $705.98 Million | -$56.27 Million | 0.65x | N/A |
| 2023 | $488.53 Million | $461.55 Million | $15.34 Million | 1.06x | 31.85x |
| 2024 | $390.07 Million | $370.23 Million | -$75.10 Million | 1.05x | N/A |
| 2025 | $554.85 Million | $326.31 Million | -$22.98 Million | 1.70x | N/A |
Competitor Companies of 300289 by Market Capitalization
Companies near Beijing Leadman Biochemistry Co Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to Beijing Leadman Biochemistry Co Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #147 globally with a market cap of $153.73 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #207 globally with a market cap of $117.79 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #234 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #247 globally with a market cap of $101.86 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #147 | Abbott Laboratories | NYSE:ABT | $153.73 Billion | $88.41 |
| #207 | Stryker Corporation | NYSE:SYK | $117.79 Billion | $307.80 |
| #234 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #247 | Medtronic PLC | NYSE:MDT | $101.86 Billion | $79.34 |
Beijing Leadman Biochemistry Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Beijing Leadman Biochemistry Co Ltd's market cap moved from $1.56 Billion to $ 467.29 Million, with a yearly change of -9.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥467.29 Million | -15.78% |
| 2025 | CN¥554.85 Million | +42.24% |
| 2024 | CN¥390.07 Million | -20.16% |
| 2023 | CN¥488.53 Million | +6.77% |
| 2022 | CN¥457.55 Million | -28.39% |
| 2021 | CN¥638.93 Million | +37.01% |
| 2020 | CN¥466.33 Million | +1.39% |
| 2019 | CN¥459.92 Million | -11.68% |
| 2018 | CN¥520.77 Million | -28.02% |
| 2017 | CN¥723.48 Million | -26.06% |
| 2016 | CN¥978.46 Million | -37.17% |
| 2015 | CN¥1.56 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Beijing Leadman Biochemistry Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $467.29 Million USD |
| MoneyControl | $467.29 Million USD |
| MarketWatch | $467.29 Million USD |
| marketcap.company | $467.29 Million USD |
| Reuters | $467.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Beijing Leadman Biochemistry Co Ltd
Beijing Leadman Biochemistry Co.,Ltd. researches and develops, manufactures, and sells vitro diagnostic reagents and instruments, and biochemical raw materials in the People's Republic of China. The company offers biochemical raw materials, including enzymes, antigens, coenzymes, antibodies, buffers, enzyme substrates, culture mediums, stain agents, amino acids, and other products for biotechnolo… Read more